1
|
Hu M, Zheng M, Wang C, Li Q, Li J, Zhou X, Ying X, Quan S, Gu L, Zhang X. Andrographolide derivative Andro-III modulates neuroinflammation and attenuates neuropathological changes of Alzheimer's disease via GSK-3β/NF-κB/CREB pathway. Eur J Pharmacol 2024; 965:176305. [PMID: 38160932 DOI: 10.1016/j.ejphar.2023.176305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 11/23/2023] [Accepted: 12/21/2023] [Indexed: 01/03/2024]
Abstract
Andrographolide has anti-inflammatory and neuroprotective effects, making it a potential therapeutic option for Alzheimer's disease (AD). Our research group optimized its structure in a previous study to minimize the risk of renal toxicity, which would beneficial for future clinical research. This study aims to examine the impact of Andro-III on enhancing cognitive learning ability in 3xTg-AD mice, as well as the mechanisms involved. Andro-III improved spatial learning ability, prevented the loss of Nysted's vesicles, reduced the accumulation of β-amyloid (Aβ) and tau proteins, and suppressed microglial activation. Further research found that the expression of nuclear factor kappa-B RelA (NF-κB p65) expression and glycogen synthase kinase-3β (GSK-3β) activity were inhibited, while CREB was upregulated in brain tissue treated with Andro-III. Moreover, Andro-III downregulated the expression of IBA1 and inflammatory factors in microglial cells of mice induced by Aβ. The regulation of the GSK-3β/NF-κB/CREB pathway was similar to that observed in 3xTg-AD mice. Therefore, Andro-III modulates neuroinflammation and attenuates neuropathological changes of AD via the GSK-3β/NF-κB/CREB pathway.
Collapse
Affiliation(s)
- Min Hu
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Miao Zheng
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Can Wang
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Qin Li
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Jinhua Li
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Xuebin Zhou
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - XinYi Ying
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Shengli Quan
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China
| | - Lili Gu
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China.
| | - Xinyue Zhang
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, PR China; Hangzhou Medical College, Hangzhou, Zhejiang, 310013, PR China.
| |
Collapse
|